3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma, Follicular
67
Lymphoma, Large B-Cell, Diffuse
66
Lymphoma, Non-Hodgkin
59
Leukemia, Lymphocytic, Chronic, B-Cell
49
Lymphoma
48
Lymphoma, Mantle-Cell
28
Lymphoma, B-Cell, Marginal Zone
23
Recurrence
16
Lymphoma, B-Cell
14
Burkitt Lymphoma
11
Neoplasms
7
Leukemia
6
Lymphoma, Large-Cell, Immunoblastic
5
Lymphoma, Large-Cell, Anaplastic
5
Waldenstrom Macroglobulinemia
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Myasthenia Gravis
3
Hematologic Diseases
3
Lymphoproliferative Disorders
2
Lymphatic Diseases
2
Immunoblastic Lymphadenopathy
2
Hodgkin Disease
2
Arthritis, Rheumatoid
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Opsoclonus-Myoclonus Syndrome
1
Neuroblastoma
1
Neoplasms by Histologic Type
1
Myelodysplastic Syndromes
1
Limb-girdle muscular dystrophy, type 2C
1
Leukemia, Myeloid, Acute
1
Interventions
Fulvestrant
2
ribociclib
1
duvelisib
1
Secretin
1
Rituximab
1
NVP-BKM120
1
Letrozole
1
Everolimus
1
CA-19-9 Antigen
1
Aspirin
1
Alpelisib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Hereditary Sensory and Autonomic Neuropathies
×
Rituximab
×
Clear all
NCT02204982
2023-09-28
DYNAMO + R
SecuraBio
Phase 3
Terminated
13 enrolled
10 charts
1 FDA